T1	Participants 62 100	patients with HCV genotype 1 infection
T2	Participants 462 516	treatment-naive patients with HCV genotype 1 infection
T3	Participants 572 688	Eight hundred and ninety-one patients treated for 48 weeks with an initial ribavirin dose of 800 or 1000/1200 mg/day